CROIVALVE LIMITED

Their core work

Croivalve is an Irish medical device company developing minimally invasive transcatheter solutions for structural heart disease, with a specific focus on tricuspid valve regurgitation. They design non-surgical devices that restore heart valve function in patients too sick or elderly for open-heart surgery, targeting a large underserved population with heart failure. Their work sits at the intersection of cardiology, interventional device engineering, and clinical translation toward commercial deployment.

What they specialise in

How they've shifted over time

Croivalve appears in H2020 only in 2019-2020, so there is no long arc to analyse. Across those two grants, their focus tightened from a general heart valve restoration device (CVTVT) to a dedicated tricuspid valve therapy (Duo) serving patients with heart failure. The shift suggests they are narrowing from a broader valve concept toward a specific clinical niche where unmet need and commercial opportunity are clearest.

They are moving from a general valve-repair platform toward a productized tricuspid valve solution, which signals progress toward clinical trials and market entry.

How they like to work

Croivalve coordinates both of its H2020 projects, running lean with only three consortium partners across three countries combined. This is the classic profile of a founder-led medtech SME that keeps development in-house and brings in partners only for specific clinical or technical gaps. Expect a focused, commercially driven collaborator rather than a large-consortium integrator.

A small, tightly curated network of three unique partners spread over three countries, consistent with a medtech SME that outsources narrow competencies rather than building broad consortia.

What sets them apart

Croivalve is one of a small number of Irish medtech SMEs tackling the tricuspid valve, which is historically the most neglected of the four heart valves and has few commercially available transcatheter solutions. They combine Ireland's strong cardiovascular device ecosystem with a specific clinical thesis around patients who have no surgical option. For a partner, this means access to an advanced-stage device program in a high-value, under-served segment.

Highlights from their portfolio

• CVTVT
  Their largest H2020 grant at EUR 2.49M, funding their core non-surgical heart valve restoration technology.
• Duo
  An SME Instrument Phase 2 project dedicated to a minimally invasive device covering the full spectrum of tricuspid valve disease patients.